Bionano Genomics, Inc. (BNGO) Research
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Market snapshot
- Symbol
- BNGO
- Price
- $1.14
- Day change
- -1.72%
- Market cap
- $13.1M
- P/E ratio
- -0.20x
- 52-week range
- 1.06-5.5
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Next earnings
- in 2 months
- Analyst price target
- $46.50
Recent news
- Bionano Genomics Stock Soars As Efficiency Gains Meet Growth Story
Despite a slight year-over-year revenue dip, the stock showed resilience, gaining nearly 27% in Monday's regular session.
- Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Bionano Genomics, Inc. (NASDAQ: BNGO) will release earnings results for its fourth quarter, after the closing bell on Monday, March 23.
- Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Bionano Genomics, Inc. (BNGO) will release Q4 earnings on March 23. Analysts expect $1.40 loss per share on $7.85M revenue. Stock closed at $1.12.
Peer companies
Recent insider activity
- Dixon Jonathan V. — F-InKind (24 shares) on 2026-06-03
- OLDAKOWSKI MARK — F-InKind (27 shares) on 2026-06-03
- Chaubey Alka — F-InKind (24 shares) on 2026-06-03
- Adamchak Mark — F-InKind (7 shares) on 2026-06-03
- Rajkovic Aleksandar — A-Award (9149 shares) on 2026-05-14
Open Bionano Genomics, Inc. (BNGO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.